[The dapagliflozin and prevention of adverse outcomes in chronic kidney disease: results of the DAPA-CKD study].

Thus, dapagliflozin demonstrated the ability, in comparison with placebo, to reduce the primary composite point and a number of secondary composite points in patients with both diabetic and non-diabetic CKD.